OppHub America Desk · · Source: yahoo-tickers-tape-movers
Eli Lilly Stock Returns Highlight Pharma Growth Potential
Investors looking for significant growth potential in the pharmaceutical sector may consider companies with strong drug pipelines and demonstrated market success. While past performance is not indicative of future results, Eli Lilly's historical returns highlight the potential for long-term wealth creation in this industry.
Based on reporting from yahoo-tickers-tape-movers.
An investment in Eli Lilly made five years ago would have yielded substantial returns, significantly outperforming the S&P 500. This performance underscores the potential for significant growth in the pharmaceutical sector driven by drug development and regulatory approvals.
Market context for this story
As of: After HoursLoading quotes…
Informational only — not investment advice. Full markets →
$SPYSPDR S&P 500 ETF
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/SPY and related $LLY. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
An initial investment of $5,000 in Eli Lilly (LLY) five years ago would have grown to approximately $23,143, representing a compound annual growth rate (CAGR) of 35.86%. This performance far exceeds the S&P 500's CAGR of 12.82% over the same period, which would have turned $5,000 into $9,139. The strong returns are attributed to factors such as the successful development and approval of key drugs like tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management.
Analysts anticipate Eli Lilly's earnings per share (EPS) to grow at an average of 20% over the next five years. The company has also demonstrated strong gross margins of 83.40% and a dividend yield of 0.60%.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Investors looking for significant growth potential in the pharmaceutical
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).